Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Chief Medical Officer | June 17, 2019 | June 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date June 17, 2019 · Filed June 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2024-06-17 | Direct | 20,000 |
Reported balance
After 2019-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-17 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the shares will vest in 6 equal monthly installments, with the first vesting date on July 31, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares will vest in 6 equal monthly installments, with the first vesting date on July 31, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2019 Filed Jun 19, 2019 16:01 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0000899243-19-017407 · doc4.xml · derivative · entry 1 Tasker Sybil · CIK 0001705900 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2024-06-17 F1 · derivative.exercise_date: 100% of the shares will vest in 6 equal monthly installments, with the first vesting date on July 31, 2019. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 17:49 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 38,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0000925421-19-000137 · edgar.xml · derivative · entry 1 Tasker Sybil · CIK 0001705900 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock, par value $0.0001 · 38,000 shares Expires 2029-03-26 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:59 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 30,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001012975-19-000029 · edgar.xml · derivative · entry 1 Tasker Sybil · CIK 0001705900 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, par value $0.0001 · 30,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| May 21, 2018 Filed May 23, 2018 17:26 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 50,016 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001012975-18-000459 · edgar.xml · derivative · entry 1 Tasker Sybil · CIK 0001705900 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,016 Underlying: Common Stock, par value $0.0001 · 50,016 shares Expires 2028-05-21 F1 · derivative.exercise_date: Twenty-five percent of the option becomes vested and exercisable on March 1, 2019, and the aggregate unvested remaining portion will vest and become exercisable in equal monthly installments on the first day of each month over the 36-month period starting April 1, 2019. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 18:37 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001012975-17-000722 · edgar.xml · derivative · entry 1 Tasker Sybil · CIK 0001705900 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock, par value $0.0001 · 50,000 shares Expires 2027-09-22 F1 · derivative.exercise_date: On the first anniversary of the date of grant, 25% of the unvested portion of the option will become vested and exercisable, and the aggregate remaining unvested portion will vest and become exercisable in equal monthly installments over the 36-month period following such anniversary date. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 16:26 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 40,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001012975-17-000478 · edgar.xml · derivative · entry 1 Tasker Sybil · CIK 0001705900 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock, par value $0.0001 · 40,000 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests and becomes exercisable in four equal annual installments commencing on the first anniversary of the date of grant. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 48,691 | Not disclosed Strike: $13.38 | Not disclosed |
DisclosureSEC source: 0000899243-17-012364 · doc4.xml · derivative · entry 1 Tasker Sybil · CIK 0001705900 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,691 Underlying: Common Stock, par value $0.0001 · 48,691 shares Expires 2026-04-07 F2 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. F1 · derivative.exercise_date: The option is currently exercisable to purchase 16,250 shares of the Issuer's common stock, par value $0.0001. An additional 25% of the option will vest on each of 4/8/2018, 4/8/2019, and 4/8/2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.